| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes SPH Alexander, D Fabbro, E Kelly, A Mathie, JA Peters, EL Veale, ... British journal of pharmacology 176 (S1), S297-S396, 2019 | 498 | 2019 |
| The Concise Guide to PHARMACOLOGY 2021/22: Enzymes SPH Alexander, D Fabbro, E Kelly, A Mathie, JA Peters, EL Veale, ... British journal of pharmacology 178, S313-S411, 2021 | 369 | 2021 |
| The concise guide to pharmacology 2023/24: enzymes SPH Alexander, D Fabbro, E Kelly, AA Mathie, JA Peters, EL Veale, ... British journal of pharmacology 180, S289-S373, 2023 | 48 | 2023 |
| Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19 NA Helsby, KE Burns Frontiers in genetics 3, 2012 | 38 | 2012 |
| The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes NA Helsby, M Yong, M van Kan, JR de Zoysa, KE Burns British Journal of Clinical Pharmacology 85 (9), 1925-1934, 2019 | 33 | 2019 |
| CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity KE Burns, MA Goldthorpe, F Porteus, P Browett, NA Helsby Cancer chemotherapy and pharmacology 73 (3), 651-655, 2014 | 20 | 2014 |
| Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients N Helsby, M Yong, K Burns, M Findlay, D Porter Cancer chemotherapy and pharmacology 88 (3), 533-542, 2021 | 17 | 2021 |
| A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes M van Kan, KE Burns, NA Helsby Cancer Chemotherapy and Pharmacology 88 (5), 755-769, 2021 | 10 | 2021 |
| Indirect regulation of CYP2C19 gene expression via DNA methylation KE Burns, P Shepherd, G Finlay, MD Tingle, NA Helsby Xenobiotica 48 (8), 781-792, 2018 | 9 | 2018 |
| A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells M van Kan, KE Burns, P Browett, NA Helsby Scientific Reports 9 (1), 18912, 2019 | 8 | 2019 |
| Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk KE Burns, O Chavani, SH Jeong, JA Duley, D Porter, M Findlay, ... Cancer Chemotherapy and Pharmacology 87 (5), 711-716, 2021 | 6 | 2021 |
| Circulating microRNA as biomarkers of clozapine-induced cardiotoxicity KE Burns, KD Deane-Alder, BL Bellissima, MD Tingle Biomarkers 25 (1), 76-85, 2020 | 6 | 2020 |
| High CYP2C19 phenotypic variability in gastrointestinal cancer patients KE Burns, WY Lo, MP Findlay, K Sharples, G Laking, NA Helsby Cancer chemotherapy and pharmacology 77 (1), 195-204, 2016 | 6 | 2016 |
| Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other … SH Jeong, O Chavani, K Burns, D Porter, M Findlay, N Helsby European Journal of Drug Metabolism and Pharmacokinetics 46 (6), 817-820, 2021 | 4 | 2021 |
| Cytochrome P450 in GtoPdb v. 2021.2 KE Burns, NA Helsby IUPHAR/BPS Guide to Pharmacology CITE 2021 (2), 2021 | 4 | 2021 |
| Cytochrome P450 (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database K Burns, N Helsby IUPHAR/BPS Guide to Pharmacology CITE 2019 (4), 2019 | 4* | 2019 |
| Ethnic disparity in clozapine dosing and cardiotoxicity in New Zealand KE Burns, BL Bellissima, F Garavan, NA Helsby, MD Tingle The New Zealand Medical Journal (Online) 135 (1555), 32-40, 2022 | 3 | 2022 |
| Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes M Yong, KE Burns, J de Zoysa, NA Helsby Xenobiotica 51 (10), 1188-1198, 2021 | 3 | 2021 |
| A case–control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine‐induced gastrointestinal toxicity NA Helsby, J Duley, KE Burns, C Bonnet, SH Jeong, E Brenman, ... British journal of clinical pharmacology 86 (1), 155-164, 2020 | 3 | 2020 |
| A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells KE Burns, D Allright, D Porter, MP Findlay, NA Helsby Cancer chemotherapy and pharmacology 84 (4), 739-748, 2019 | 2 | 2019 |
Nuala Ann HelsbyAssociate Professor, University of AucklandVerified email at auckland.ac.nz
